Blanket Purchase Agreement 36F79721D0249-36C24723A0017
Award Date
4/1/23
Last Date to Order
6/30/23
Federal Agency
Veterans Integrated Service Network 7
Awardee
CSL Behring L.L.C.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025. The VA Greater Los Angeles Healthcare System...
CSL Behring L.L.C., a global biotherapeutics company, holds a $201,482,280 Federal Supply Schedule (FSS-61-IB) contract for Pharmaceuticals and Drugs with the U.S. Department of Veterans Affairs (VA). This indefinite delivery vehicle enables VA facilities nationwide to efficiently procure critical pharmaceutical products from CSL Behring, including specialty medications like HAEGARDA used to treat hereditary angioedema. The company also has two Blanket Purchase Agreements (BPAs) with the VA -...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 awarded multiple blanket purchase agreement calls against the Pharmaceuticals and Drugs Federal Supply Schedule to CSL Behring L.L.C. totaling over $20 million. The BPAs provide for the delivery of pharmaceutical products including the intravenous immunoglobulin Privigen to various VA medical facilities located in Pennsylvania, Florida, and Georgia. Performance will take place in King of...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Vanda Pharmaceuticals Inc. (Vanda) on September 6, 2024. The BPA has a ceiling value of $3,753,465.00 and a period of performance through September 5, 2025. The primary product being procured under this BPA is Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Regeneron Pharmaceuticals Inc. for the base year plus four option periods with a potential value of $780,000. The BPA utilizes the Pharmaceuticals and Drugs Federal Supply Schedule and has no set-aside designated. The agreement facilitates the procurement of the drugs Arcalyst and Evkeeza to support the Department of Veterans Affairs' medical programs. Arcalyst treats recurrent...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Fera Pharmaceuticals, LLC, a woman-owned small business. The BPA, valued at up to $255,000, is for the procurement of Phospholine Iodide, a pharmaceutical drug. The BPA was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and allows the VA and other agencies to efficiently and compliantly acquire the needed pharmaceutical product from Fera...